Hong Kong's bourse operator has proposed new measures to bolster initial public offerings, a move that is expected to further ...

After a lengthy downturn, renewed optimism is building among young drugmakers and their backers as a new funding wave takes shape, said Santé Ventures’ Omar Khalil.

More than 10 pre-profit drug developers are seeking Hong Kong listings as AI-powered biotech platforms draw growing investor ...

BioVie is eyeing a $19.7 million IPO for a spinout focused on bringing a new formulation of an approved kidney failure drug to market as a potential treatment for liver disease. | BioVie is eyeing a ...

Salspera has set out plans for a $91 million IPO to fund the phase 3 study of its bacteria-based cancer therapy. | Salspera has set out plans for a $91 million IPO to fund the phase 3 study of its ...

Generate Biomedicines IPO highlights AI-driven drug discovery, strong backing, promising pipeline, and investor confidence signals.

Chungui International BioTech Group has filed for an initial public offering. The consumer goods company said it will sell 3 million units at $5 apiece, according to a filing with the Securities and ...

Beijing Tong Ren Tang Healthcare Investment, a subsidiary of major Hong Kong-listed traditional Chinese medicine group Tong Ren Tang, plans to raise up to HK$897.7 million by offering 108.2 million ...

Detailed price information for Renaissance IPO ETF (IPO-A) from The Globe and Mail including charting and trades.

Gov. Maura Healey is using a new executive order to procure more energy supply and storage in Massachusetts, an effort her ...

Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.